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Abstract
Adoptive transfer of CD4+CD25+ regulatory T cells has been
shown to have therapeutic effects in animal models of
autoimmune diseases. Chemokines play an important role in the
development of autoimmune diseases in animal models and
humans. The present study was performed to investigate
whether the progression of organ-specific autoimmune
diseases could be reduced more markedly by accumulating
chemokine receptor-expressing CD4+CD25+ regulatory T cells
efficiently in target organs in MRL/MpJ-lpr/lpr (MRL/lpr) mice.
CD4+CD25+Foxp3+  T cells (Treg cells) and
CD4+CD25+Foxp3+  CCR2-transfected T cells (CCR2-Treg
cells) were transferred via retro-orbital injection into 12-week-
old MRL/lpr mice at the early stage of pneumonitis and
sialadenitis, and the pathological changes were evaluated.
Expression of monocyte chemoattractant protein-1 (MCP-1)/
CCL2 was observed in the lung and submandibular gland of the
mice and increased age-dependently. The level of CCR2
expression and MCP-1 chemotactic activity of CCR2-Treg cells
were much higher than those of Treg cells. MRL/lpr mice to
which CCR2-Treg cells had been transferred showed
significantly reduced progression of pneumonitis and
sialadenitis in comparison with MRL/lpr mice that had received
Treg cells. This was due to more pronounced migration of
CCR2-Treg cells and their localization for a longer time in MCP-
1-expressing lung and submandibular gland, resulting in
stronger suppressive activity. We prepared chemokine
receptor-expressing Treg cells and demonstrated their ability to
ameliorate disease progression by accumulating in target
organs. This method may provide a new therapeutic approach
for organ-specific autoimmune diseases in which the target
antigens remain undefined.
Introduction
CD4+CD25+ regulatory T cells are critical for the regulation of
host tolerance and are considered to have enormous potential
for suppressing pathological immune responses in autoim-
mune disease, transplantation, and graft-versus-host disease
(GVHD) [1,2]. These cells express a specific transcription fac-
tor, forkhead box p3 (Foxp3), which has been associated with
their development and suppressive function [3-5]. The mech-
anism by which CD4+CD25+  regulatory T cells suppress
immune responses is poorly understood, but these cells
appear to suppress a variety of reactions, including CD4+ and
CD8+ T-cell responses as well as B-cell responses [6,7].
CD4+CD25+ regulatory T cells have also been reported to act
directly on natural killer (NK), natural killer T (NKT), and den-
dritic cells [8-10]. Therefore, the suppressive characteristics
of CD4+CD25+ regulatory T cells have made them an attrac-
tive candidate for immunotherapy, and numerous studies
using animal models have demonstrated their potential for the
control of autoimmune diseases as well as transplant rejection
and GVHD.
CCR2-Treg cell = CD4+CD25+Foxp3+ CCR2-transfected T cell; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; Foxp3 = 
forkhead box p3; GVHD = graft-versus-host disease; HPRT1 = hypoxanthine phosphoribosyl transferase 1; IC = immune complex; IL-2 = interleukin-
2; IP-10 = interferon-inducible protein 10; MCP-1 = monocyte chemoattractant protein-1; MoAb = monoclonal antibody; MRL/lpr = MRL/MpJ-lpr/
lpr; NK = natural killer; NKT = natural killer T; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; qPCR = quantitative real-time 
polymerase chain reaction; Treg cell = CD4+CD25+Foxp3+ T cell.Arthritis Research & Therapy    Vol 9 No 1    Hasegawa et al.
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CD4+CD25+ regulatory T cells account for only 5% to 10% of
the total CD4+ population in both mice and humans [1,2].
Therefore, administration of sufficient numbers of freshly iso-
lated CD4+CD25+ regulatory T cells is not therapeutically
practical, and it is critically important to expand the number of
CD4+CD25+ regulatory T cells to facilitate their accumulation
in target organs for clinical immunotherapy. Recent studies
have shown that suppressive properties and organ-specific
tolerance are critically dependent on the antigen specificity of
CD4+CD25+  regulatory T cells and that antigen-specific
CD4+CD25+ regulatory T cells are more effective for disease
protection than polyclonal CD4+CD25+ regulatory T cells,
which means that lower numbers of CD4+CD25+ regulatory T
cells are needed for therapy [11-16]. Thus, it seems likely that
therapy using antigen-specific CD4+CD25+ regulatory T cells
has the most potential for treatment of autoimmune diseases
in which target antigens have been identified. However, in the
majority of autoimmune diseases in humans, relevant organ-
specific antigens remain undefined. Accordingly, we noticed
that the chemokine-receptor system accumulates
CD4+CD25+ regulatory T cells efficiently in target organs.
Chemokines play an important role in the pathogenesis of
autoimmune diseases in murine models and humans [17,18].
The MRL/MpJ-lpr/lpr (MRL/lpr) mouse strain spontaneously
develops a severe generalized autoimmune disease resem-
bling systemic lupus erythematosus [19], characterized by sia-
ladenitis, interstitial pneumonitis, lupus nephritis, vasculitis,
arthritis, and lymphadenopathy. The major immunopathologi-
cal phenomenon observed in sialadenitis and pneumonitis is
infiltration of mononuclear cells, especially CD4+ T cells. We
and others have shown that local generation of chemokines
and the presence of chemokine receptors on the infiltrating
cells play a critical role in the initiation and progression of
autoimmune disease in MRL/lpr mice [20-27]. Monocyte che-
moattractant protein-1 (MCP-1)/CCL2 and interferon-induci-
ble protein-10 (IP-10)/CXCL10 have been reported to be
involved in the process of sialadenitis and pneumonitis in
MRL/lpr mice [22-24,26,27].
In the present study, we prepared CD4+CD25+ regulatory T
cells in which the receptor for MCP-1, CCR2, was highly
expressed. Then, we characterized the CCR2-expressing
CD4+CD25+ regulatory T cells and their therapeutic effect on
sialadenitis and pneumonitis by accumulating them in target
organs in MRL/lpr mice.
Materials and methods
Mice and cells
MRL/lpr mice (H-2k) were purchased from The Jackson Labo-
ratory (Bar Harbor, ME, USA)). MRL/Mp-+/+ (MRL/+) mice
(H-2k) and DBA/1 mice (H-2q) were purchased from Japan
SLC, Inc. (Shizuoka, Japan). This study was approved by the
animal ethics committee of Ehime University (Ehime, Japan).
The packaging cell line, PLAT-E, was kindly provided by Prof.
Toshio Kitamura (Institute of Medical Science, University of
Tokyo, Tokyo, Japan). PLAT-E cells were maintained in Dul-
becco's modified Eagle's medium supplemented with 10%
heat-inactivated fetal calf serum (FCS) (Life Technologies,
Inc., now part of Invitrogen Corporation, Carlsbad, CA, USA).
Antibodies and reagents
Biotin-conjugated anti-mouse MCP-1 goat polyclonal antibody
was obtained from R&D Systems, Inc. (Minneapolis, MN,
USA). The hamster anti-mouse CD3e rat monoclonal antibody
(MoAb) (145-2C11) was purchased from BD Biosciences
(San Jose, CA, USA). Mouse MCP-1 and interleukin-2 (IL-2)
were obtained from R&D Systems, Inc.
In vitro expansion of CD4+CD25+ T cells
The CD4+CD25+ T cells were purified from spleen cells of
MRL/+ mice using a CD4+CD25+ regulatory T-cell isolation kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) according to
the manufacturer's recommendation. The purity of the
CD4+CD25+ T cells was ascertained by flow cytometry analy-
sis using specific antibodies labeled with phycoerythrin or flu-
orescein isothiocyanate and was found to be more than 95%.
One hundred thousand CD4+CD25+ T cells were plated in
24-well flat-bottom plates coated with 5 μg/ml anti-mouse
CD3e MoAb in a final volume o f  2  m l  o f  c o m p l e t e  R P M I
medium (RPMI-1640 medium supplemented with 10% FCS,
2 mM l-glutamine, 2 × 10-5 M 2-mercaptoethanol, 100 IU/ml
penicillin, and 100 μg/ml streptomycin) in the presence of 2
μg/ml anti-mouse CD3e MoAb and 20 ng/ml IL-2 with 4 × 105
irradiated (15 Gy) syngeneic splenocytes as feeder cells that
had been depleted of T cells by negative selection using a
mouse Pan T-cell isolation kit (Miltenyi Biotec) according to
the manufacturer's protocol. The medium was changed, anti-
mouse CD3e MoAb and IL-2 were added every 3 to 4 days,
and fresh feeder cells were added every 10 to 14 days.
Construction of mouse CCR2 or Foxp3 gene expression 
retroviral vectors and production of recombinant 
retrovirus
The pMXs-IG and pMXs-IR retroviral vectors [28] were kindly
provided by Prof. T Kitamura. The pMXs-IG and pMXs-IR ret-
roviral vectors contain a green fluorescent protein and a red
fluorescent protein, respectively. The pMXs-IG-mCCR2 vec-
tor, in which the fragment containing the coding region of
mouse CCR2 gene was inserted into the SalI-NotI site of the
pMXs-IG vector, was kindly provided by Prof. Osamu Yoshie
(Kinki University School of Medicine, Osaka, Japan). The frag-
ment containing the coding region of the mouse Foxp3 gene
was inserted into the EcoRI-NotI site of the pMXs-IR vector.
The recombinant retrovirus was produced as described by
Kitamura and colleagues [29]. Briefly, 2 × 106 PLAT-E cells
were seeded onto 60-mm dishes 1 day before transfection
using FuGENE 6 transfection reagent (Roche Diagnostics,Available online http://arthritis-research.com/content/9/1/R15
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Indianapolis, IN, USA) according to the manufacturer's proto-
col. Cells were cultured for 48 hours and then the retroviral
supernatant was stocked for infection of target cells. The esti-
mated titers of the retroviruses were 1 × 106 to 3 × 106 infec-
tious units per milliliter based on the infected NIH3T3 cells.
Infection and expression of recombinant retroviruses
Infection and expression of recombinant retroviruses into
CD4+CD25+ T cells were performed as described by Kita-
mura and colleagues [29]. First, we prepared
CD4+CD25+Foxp3+ T cells (Treg cells) by infection of recom-
binant retrovirus carrying the pMXs-IR-Foxp3 vector into
CD4+CD25+ T cells. One million cultured CD4+CD25+ T cells
were suspended with virus stock that had been adjusted to a
multiplicity of infection of 5 and then were centrifuged at
1,000g for 2 hours at 32°C. These cells then were grown in
complete RPMI medium in the presence of anti-CD3e MoAb
and IL-2 with irradiated syngeneic splenocytes. After 2 days,
Treg cells were isolated by sorting the highly expressed popu-
lation. Next, CD4+CD25+Foxp3+ CCR2-transfected T cells
(CCR2-Treg cells) were isolated by fluorescence-activated
cell sorting after infection with recombinant retrovirus carrying
the pMXs-IG-mCCR2 vector into the above Treg cells as
described above.
Total RNA preparation, cDNA synthesis, and real-time 
polymerase chain reaction for MCP-1, CCR2, and Foxp3
The expressions of MCP-1, CCR2, and Foxp3 were quantified
by real-time polymerase chain reaction (PCR). Briefly, for
quantitative real-time PCR (qPCR) analysis, total RNAs were
extracted from cultured cells, snap-frozen lungs, and sub-
mandibular glands using TRIZOL reagent (Invitrogen Corpora-
tion). The cDNA was prepared with a SuperScript™  III
CellsDirect cDNA synthesis system (Invitrogen Corporation).
The expressions of the MCP-1, CCR2, and Foxp3 genes were
quantified using a QuantiTect™ SYBR Green PCR kit (Qiagen
Inc., Valencia, CA, USA) in a 7500 Real Time PCR System
(Applied Biosystems Japan Ltd., Tokyo, Japan) and were cor-
rected with a hypoxanthine phosphoribosyl transferase 1
(HPRT1) control. Amplifications were carried out in a total vol-
ume of 25 μl for 45 cycles of 15 seconds at 95°C and 1
minute at 60°C. Samples were run in triplicate and their rela-
tive expression was determined by normalizing the expression
of each target to HPRT1 and then comparing this normalized
value with the normalized expression in a reference control
sample to calculate the fold-change value. The primers for the
amplicons spanned intron/exon boundaries to minimize any
amplification of genomic DNA. The primer sequences were as
follows:  MCP-1, forward 5'-CCAACTCTCACT-
GAAGCCAGCTC-3' and reverse 5'-TTGGGATCATCTT-
GCTGGTGAA-3';  CCR2, forward 5'-
TTACCTCAGTTCATCCACGG-3' and reverse 5'-TCATCG-
TAGTCATACGGTGT-3'; Foxp3, forward 5'-CCCAGGAAA-
GACAGCAACCTT-3' and reverse 5'-
TTCTCACAACCAGGCCACTTG-3'; and HPRT1, forward 5'-
CAGGCCAGACTTTGTTGGAT-3' and reverse 5'-
TTGCGCTCATCTTAGGCTTT-3'.
Adoptive transfer
Cultured Treg cells and CCR2-Treg cells (1 × 105 or 5 × 105
cells) were transferred through retro-orbital venous plexus into
12-week-old MRL/lpr mice (at the early stage of sialadenitis
and pneumonitis) twice every 2 weeks. To examine the patho-
logical alterations, the mice were sacrificed 3 weeks after the
last injection (that is, when the mice were 17 weeks old).
To examine the kinetics of cells remaining in the lungs and sub-
mandibular glands, 5 × 105 Treg cells or CCR2-Treg cells
were injected into the retro-orbital vein of 14-week-old MRL/
lpr mice. Then, the lungs and submandibular glands were har-
vested at 3 hours, 24 hours, 72 hours, 5 days, and 7 days after
injection.
Preparation of mononuclear cells from lungs and 
submandibular glands
Mice were sacrificed at each time point after injection of Treg
cells and CCR2-Treg cells. The chest cavity was opened by
sterile surgical dissection, and the inferior vena cava and
abdominal aorta were clamped. The left atrium was opened by
incision, and the right ventricle was infused with sterile phos-
phate-buffered saline (PBS) to remove any residual blood in
the pulmonary vasculature. The right lung and submandibular
gland were removed, snap-frozen in liquid nitrogen, and stored
at -80°C for extraction of total RNA. The right lung and sub-
mandibular gland were cut into small pieces and placed in
RPMI-1640 medium containing 5% FCS, 1 mg/ml colla-
genase (Sigma-Aldrich, St. Louis, MO, USA), and 100 units
per milliliter DNase (Takara Shuzo Co., Ltd., Kyoto, Japan).
After 30 minutes of collagenase digestion in a 37°C water
bath, these tissues were further disrupted by aspiration
through an 18-gauge needle. The collagenase-digested tis-
sues were then subjected to Ficoll centrifugation. The inter-
face between the medium and the Ficoll was removed and
washed twice with RPMI-1640 medium containing 5% FCS.
The staining cells were examined on an Olympus IX70 inverted
microscope (Olympus, Tokyo, Japan).
Immunohistochemistry
To detect MCP-1 expression, formalin-fixed sections were
deparaffinized and analyzed by the avidin-biotin-peroxidase
method, using biotin-labeled goat anti-murine MCP-1 polyclo-
nal antibody as described previously [20]. Preimmune biotin-
labeled goat serum served as a negative control.
Evaluation of sialadenitis and pneumonitis
Tissues were fixed in 10% formalin for 24 hours at 4°C, and
then paraffin sections were prepared, stained with hematoxylin
and eosin. The degree of sialadenitis in the submandibular
glands was categorized as 0, normal; 1, mild (cell infiltration
localized in the perivascular and/or periductal regions); 2,Arthritis Research & Therapy    Vol 9 No 1    Hasegawa et al.
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moderate (cell infiltration not only localized in the perivascular
and/or periductal regions but also extending to the paren-
chyma); or 3, severe (cell infiltration localized in the perivascu-
lar and/or periductal regions, with fibrosis and/or granuloma).
The sialadenitis index was indicated as the sum of all the
scores per section divided by the sum of all vessels and all
ducts per section.
The perivascular and peribronchiolar infiltrates were scored on
the basis of histopathological findings: 0, normal; 1, less than
three cell layers; 2, three to six cell layers; or 3, more than six
layers. The index of perivascular lesion was indicated as the
sum of all the scores per section divided by the number of all
vessels per section. The index of peribronchiolar lesion was
indicated as the sum of all the scores per section divided by
the number of all bronchioli per section.
The infiltrates in alveolar areas in high-power fields (× 400
magnification) were scored as follows: 0, no infiltrating mono-
nuclear cells; 1, less than 10 infiltrating cells; 2, less than 20
infiltrating cells; or 3, more than 20 infiltrating cells. The alveo-
lar lesions index was indicated as the mean value of 20 ran-
dom fields per section. The sections were evaluated by one of
us, who was blinded to the treatment given.
Chemotactic assay
Chemotactic assays for cultured Treg cells and CCR2-Treg
cells were performed in polycarbonate-membrane, 6.5-mm
diameter, 5-μm-pore-size transwell cell culture chambers
(Costar Corp, now part of Corning Life Sciences, Acton, MA,
USA) as described previously [30]. Aliquots (100 μl) of cells
(5 × 106 per milliliter) suspended in RPMI-1640/0.5% bovine
serum albumin were added to the upper chambers. The MCP-
1 was added to the lower wells at various concentrations. The
cells were allowed to migrate for 2 hours at 37°C in a 5% CO2
incubator, after which the filters were fixed with 1% glutaralde-
hyde in PBS for 30 minutes and stained with 0.5% toluidine
blue overnight. Cell migration was quantified by counting the
cells in each lower chamber and cells adhering to the bottom
of the polycarbonate filter.
In vitro suppression assay
To test the suppressive action of cultured Treg cells and
CCR2-Treg cells on alloantigen stimulation, 1 × 105 freshly
isolated CD3+ T cells from MRL/+ mice were stimulated with
1 × 105 irradiated (15 Gy) allogeneic splenocytes from DBA1
mice. Graded numbers (1.25 × 104, 2.5 × 104, 5 × 104, or 1
× 105) of the above cultured cells were added to the cultures,
and the cells were cocultured in a final volume of 200 μl of
complete RPMI medium in 96-well round-bottom plates for 4
days. The wells were pulsed with 1 μCi [3H]thymidine (Amer-
sham Biosciences, now part of GE Healthcare, Little Chalfont,
Buckinghamshire, UK) 18 hours before harvesting.
Evaluation of circulating immune complexes and anti-
DNA antibody
The levels of circulating immune complexes (ICs) and anti-
DNA antibody were measured by enzyme-linked immunosorb-
ent assay (ELISA) as described previously [31]. Briefly, ELISA
plates were coated with 10 μg/ml human C1q (Sigma-Aldrich)
for measurement of circulating ICs or with 5 μg/ml double-
stranded calf thymus DNA (Sigma-Aldrich) for measurement
of anti-DNA antibody.
Results
MCP-1 expression in lungs and submandibular glands of 
MRL/lpr mice
MRL/lpr mice demonstrated progressive development of
pneumonitis and sialadenitis, which became noticeable at 10
to 12 weeks of age. In pneumonitis, mononuclear cell infiltra-
tion became noticeable in the perivascular, peribronchial, and
alveolar areas. Lesion severity increased with the number of
inflammatory cells in the pulmonary parenchyma. Interstitial
fibrosis and alveolar atelectasis were observed in the later
phase. In sialadenitis, small focal infiltrates of inflammatory
cells (< 50 cells) were located predominantly around the
blood vessels. After 12 weeks of age, larger infiltrates of
mononuclear cells, especially CD4+ T cells, became apparent
in the periductular regions, extending to the parenchyma and
resulting in parenchymal destruction.
First, we analyzed the expression of MCP-1 mRNA by qPCR
of total RNA from lungs and submandibular glands during dis-
ease development in MRL/lpr mice. As shown in Figure 1a,
MRL/lpr mice began to show a significant increase in both
lung and submandibular gland MCP-1 mRNA at 12 weeks of
age and exhibited progressive increases in MCP-1 expression
from 12 to 20 weeks of age. The MCP-1 mRNA levels in lungs
of 16- and 20-week-old mice were 20- and 56-fold higher,
respectively, than those of 12-week-old mice, whereas the
corresponding levels for submandibular glands of 16- and 20-
week-old mice were six- and seven-fold higher, respectively,
than those of 12-week-old mice. In addition, the level of MCP-
1  expression in the lung was higher than that in the sub-
mandibular gland.
To clarify the localization of MCP-1 expression, immunohisto-
logical staining of lung and submandibular gland tissues was
performed during disease development (Figure 1b). MCP-1
was expressed significantly in these organs in 16-week-old
MRL/lpr mice compared with those in 8-week-old MRL/lpr
mice. In the lung, MCP-1 was expressed predominantly in alve-
olar epithelial cells, macrophages, vascular endothelial cells,
and interstitial cells and was also observed occasionally in
bronchiolial epithelial cells. In the submandibular gland, MCP-
1 was expressed mainly in infiltrating macrophages/mono-
cytes and interstitial cells, but no expression was observed in
the ductal epithelium.Available online http://arthritis-research.com/content/9/1/R15
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Characterization of Treg cells and CCR2-Treg cells
The CD4+CD25+ T cells were separated with microbeads and
then cultured with irradiated syngeneic splenocytes in the
presence of anti-mouse CD3e MoAb and IL-2. However, after
2 weeks of culture, 10% to 30% of the cells were
CD4+CD25+Foxp3-  T cells because contaminating
CD4+CD25- T cells grew faster than CD4+CD25+ regulatory
T cells. The cultured CD4+CD25+ T cell population, including
activated nonregulatory CD25+  T cells such as
CD4+CD25+Foxp3-  T cells, is functionally heterogeneous.
Therefore, we reprogrammed these cells by ectopic expres-
sion of Foxp3 to maintain their suppressive activity. First, we
prepared Treg cells by infection of CD4+CD25+ T cells with
recombinant retrovirus carrying the pMXs-IR-Foxp3 vector.
Next, CCR2-Treg cells were isolated after infection of the
above Treg cells with recombinant retrovirus carrying the
pMXs-IG-mCCR2 vector. There was no significant difference
in Foxp3 expression between Treg cells and CCR2-Treg cells,
and the two cell types showed similar suppressive activity dur-
ing at least 1 month (data not shown).
Expression of the CCR2 receptor in cultured Treg cells and
CCR2-Treg cells was analyzed by qPCR. As shown in Figure
2a, the expression level of CCR2 in CCR2-Treg cells was
Figure 1
Monocyte chemoattractant protein-1 (MCP-1) expression in the lungs and submandibular glands of MRL/lpr mice Monocyte chemoattractant protein-1 (MCP-1) expression in the lungs and submandibular glands of MRL/lpr mice. (a) Quantitative real-time 
polymerase chain reaction analysis was performed on total RNA prepared from lungs and submandibular glands of five mice at ages 8, 10, 12, 16, 
and 20 weeks during the development of pneumonitis and sialadenitis as described in Materials and methods. Results are calculated as a ratio of 
MCP-1 expression to the expression of hypoxanthine phosphoribosyl transferase 1 (HPRT1). (b) Representative immunohistochemistry results are 
shown. Formalin-fixed sections were deparaffinized and incubated with biotin-labeled goat anti-mouse MCP-1 polyclonal antibody, and the expres-
sion of MCP-1 was detected with avidin-biotin-peroxidase. The sections were counterstained with hematoxylin. MRL/lpr, MRL/MpJ-lpr/lpr.Arthritis Research & Therapy    Vol 9 No 1    Hasegawa et al.
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2,300-fold higher than that in Treg cells. In the MCP-1-driven
chemotactic assay, the chemotactic activity of CCR2-Treg
cells was much higher than that of Treg cells (Figure 2b).
These findings indicated that CCR2-Treg cells migrated to
MCP-1 more efficiently than Treg cells.
The suppressive properties of cultured Treg cells and CCR2-
Treg cells were examined in alloantigen-stimulated cultures.
As shown in Figure 2c, 2.5 × 104 cultured Treg cells and
CCR2-Treg cells produced a 67% and 57% reduction of the
proliferative response, respectively, and the suppressive
effects were dose-dependent. There was no significant differ-
ence in the suppressive properties between cultured Treg
cells and CCR2-Treg cells.
Evaluation of pneumonitis and sialadenitis in Treg cell- 
and CCR2-Treg cell-transferred MRL/lpr mice
Cultured Treg cells and CCR2-Treg cells were transferred via
retro-orbital injection into 12-week-old MRL/lpr mice (at the
early stage of pneumonitis and sialadenitis). Either 1 × 105 or
Figure 2
Characterization of Treg cells and CCR2-Treg cells Characterization of Treg cells and CCR2-Treg cells. (a) Expression of CCR2 gene in Treg cells and CCR2-Treg cells. Quantitative real-time 
polymerase chain reaction analysis was performed on total RNA prepared from Treg and CCR2-Treg cells. Results are calculated as a ratio of 
CCR2 expression to the expression of hypoxanthine phosphoribosyl transferase 1 (HPRT1). (b) Chemotactic activity of Treg and CCR2-Treg cells 
to monocyte chemoattractant protein-1 (MCP-1). Aliquots (100 μl) of cells (5 × 106 per milliliter) were added to the upper chambers, and MCP-1 
was added to the lower wells at various concentrations. After 2 hours, cell migration was quantified by counting cells in each lower chamber and 
cells adhering to the bottom part of the filter. Each assay was performed in triplicate. (c) Suppressive function of Treg and CCR2-Treg cells to 
alloantigen. One hundred thousand freshly isolated CD3+ T cells from MRL/+ mice were stimulated with 1 × 105 irradiated allogeneic splenocytes 
from DBA1 mice. Graded numbers of the Treg and CCR2-Treg cells were added to the cultures. Wells were pulsed with [3H]thymidine (3H-TdR) for 
the last 18 hours of the 4-day culture. Control (no addition of regulatory T cells) is 16,429 ± 5,160 cpm. CCR2-Treg cell, CD4+CD25+Foxp3+ 
CCR2-transfected T cell; Treg cell, CD4+CD25+Foxp3+ T cell.Available online http://arthritis-research.com/content/9/1/R15
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5 × 105 cells were injected into the mice twice every 2 weeks,
and then the mice were sacrificed 3 weeks after the last
injection to evaluate the pathological changes. As shown in
Figures 3 and 4, MRL/lpr mice that had undergone transfer of
either 1 × 105 or 5 × 105 CCR2-Treg cells demonstrated sig-
nificantly reduced (P < 0.01) infiltration of mononuclear cells
into the perivascular and peribronchiolar lesions and alveolar
areas in comparison with Treg cell-transferred MRL/lpr mice
(lesion index: perivascular 1.06 ± 0.14 versus 1.52 ± 0.22 and
0.70 ± 0.19 versus 1.41 ± 0.05, peribronchiolar 1.14 ± 0.10
versus 1.52 ± 0.19 and 0.65 ± 0.13 versus 1.54 ± 0.22, and
alveolar 1.02 ± 0.13 versus 1.41 ± 0.20 and 0.71 ± 0.13 ver-
sus 1.37 ± 0.11, respectively). On the other hand, there was
no significant difference of mononuclear cell infiltration in
these areas among control MRL/lpr mice and mice that had
undergone transfer of 1 × 105 or 5 × 105 Treg cells.
In sialadenitis, only MRL/lpr mice that had undergone transfer
of 5 × 105 CCR2-Treg cells showed significantly lower levels
of periductal mononuclear cell infiltration and parenchymal
destruction compared with the other four groups. No
Figure 3
Comparison of pneumonitis and sialadenitis in Treg cell- and CCR2- Treg cell-transferred MRL/lpr mice Comparison of pneumonitis and sialadenitis in Treg cell- and CCR2-
Treg cell-transferred MRL/lpr mice. Representative photographs are 
shown. Treg and CCR2-Treg cells were transferred via retro-orbital 
injection in 12-week-old MRL/lpr mice. One hundred thousand or 5 × 
105 cells were injected into mice twice every 2 weeks, and the patho-
logical changes were evaluated 3 weeks after the last injection (that is, 
when the mice were 17 weeks old). Non-treated 17-week-old MRL/lpr 
mice were used as control. CCR2-Treg cell, CD4+CD25+Foxp3+ 
CCR2-transfected T cell; HE, hematoxylin and eosin; MRL/lpr, MRL/
MpJ-lpr/lpr; Treg cell, CD4+CD25+Foxp3+ T cell.
Figure 4
Evaluation of pneumonitis and sialadenitis in Treg cell- and CCR2-Treg  cell-transferred MRL/lpr mice Evaluation of pneumonitis and sialadenitis in Treg cell- and CCR2-Treg 
cell-transferred MRL/lpr mice. The degrees of pneumonitis and sialad-
enitis of control and treated 17-week-old MRL/lpr mice were scored as 
described in Materials and methods. Values are presented as the mean 
and standard deviation (n = 5 to 7 mice per group). Similar results were 
observed in two independent experiments. *P < 0.01 versus control by 
Student's t test. CCR2-Treg cell, CD4+CD25+Foxp3+ CCR2-trans-
fected T cell; MRL/lpr, MRL/MpJ-lpr/lpr; Treg cell, CD4+CD25+Foxp3+ 
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significant difference in the severity of glomerulonephritis or
renal vasculitis was observed between Treg cell- and CCR2-
Treg cell-transferred MRL/lpr mice that had received either 1
× 105 or 5 × 105 cells (data not shown). In addition, there was
no significant difference in the production of anti-DNA anti-
body and circulating ICs among the five groups (data not
shown). These findings suggest that CCR2-Treg cells migrate
easily into MCP-1-expressing organs and show local rather
than systemic suppressive activity in a dose-dependent man-
ner. Furthermore, MRL/lpr mice that had undergone transfer of
5 × 105 CCR2-Treg cells showed a significant increase in sur-
vival compared with the other four groups (Figure 5). This is
due to marked reduction of pneumonitis.
In an additional experiment, we prepared CD4+CD25- CCR2-
transfected T cells by transduction of recombinant retrovirus
carrying the pMXs-IG-mCCR2 vector into CD4+CD25- T cells
and compared pneumonitis and sialadenitis among control,
CD4+CD25- T cell-transferred, and CD4+CD25- CCR2-trans-
ferred MRL/lpr mice. Five hundred thousand CD4+CD25- T
cells and CD4+CD25- CCR2-transfected T cells were trans-
ferred into 12-week-old MRL/lpr mice as described in Materi-
als and methods. There were no significant differences in
pneumonitis and sialadenitis among control, CD4+CD25- T
cell-transferred, and CD4+CD25- CCR2-transferred MRL/lpr
mice (lesion index: perivascular 1.48 ± 0.23 versus 1.51 ±
0.07 versus 1.35 ± 0.41, peribronchiolar 1.48 ± 0.41 versus
1.55 ± 0.22 versus 1.49 ± 0.19, alveolar 1.25 ± 0.18 versus
1.29 ± 0.17 versus 1.24 ± 0.11, and sialadenitis 1.24 ± 0.19
versus 1.19 ± 0.37 versus 1.20 ± 0.33, respectively; n = 4 per
group). Therefore, MRL/lpr mice that had undergone transfer
of CCR2-Treg cells showed significant amelioration of pneu-
monitis and sialadenitis progression in comparison with
CD4+CD25- CCR2-transferred MRL/lpr mice.
Localization of adoptively transferred Treg cells and 
CCR2-Treg cells in the lungs and submandibular glands 
of MRL/lpr mice
Next, to compare the migration of Treg cells and CCR2-Treg
cells in the lung and submandibular gland, we harvested these
organs at various times after retro-orbital injection in 14-week-
old MRL/lpr mice, examined the Foxp3  expression in each
group by qPCR, and analyzed the mononuclear cells isolated
from the lungs and submandibular glands in each group by
immunofluorescence. As shown in Figure 6, the localization of
CCR2-Treg cells to the lungs was increased more than five-
fold both at 3 hours and at 24 hours after transfer compared
with that of Treg cells, and the regional localization continued
to increase until 7 days. The kinetics of cell localization in the
submandibular glands showed a pattern similar to those in the
lungs. On the other hand, the numbers of Treg and CCR2-
Treg cells localized in the kidneys were significantly lower
(Foxp3/HPRT1 ratio at 3 hours: 0.56 ± 0.10 versus 1.94 ±
0.24, respectively) than those in the lungs and submandibular
glands, even though MCP-1 was expressed in the kidney of
14-week-old MRL/lpr mice. These findings indicate that, in
comparison with Treg cells, more CCR2-Treg cells migrate
into MCP-1-expressing lung and submandibular gland and
remain localized there for a longer time, resulting in stronger
suppressive activity.
Discussion
In the present study using a murine model, we demonstrated
the potential of a new therapeutic approach for markedly
reducing the progression of organ-specific autoimmune dis-
eases through the efficient accumulation of chemokine recep-
tor-expressing CD4+CD25+  regulatory T cells in target
organs. Our main findings were as follows: (a) MCP-1 expres-
sion was observed in the lung and submandibular gland of 12-
week-old MRL/lpr mice and increased with age, (b) Treg and
CCR2-Treg cells had almost the same suppressive properties,
(c) MCP-1-directed chemotactic activity of CCR2-Treg was
much higher than that of Treg cells, (d) MRL/lpr mice that had
undergone transfer of CCR2-Treg cells showed significant
amelioration of the progression of pneumonitis and sialadenitis
in comparison with Treg cell-transferred MRL/lpr mice, and (e)
this effect was due to the migration of higher numbers of
CCR2-Treg cells into MCP-1-expressing lung and submandib-
ular gland and their localization there for a longer time, result-
ing in stronger suppressive activity.
Figure 5
Survival of MRL/lpr mice after transfer of Treg and CCR2-Treg cells Survival of MRL/lpr mice after transfer of Treg and CCR2-Treg cells. 
Mice were observed until day 160 or death. All experiments were car-
ried out with groups of five mice. Similar results were obtained in one 
additional experiment. *P < 0.05 versus control by Student's t test. 
CCR2-Treg cell, CD4+CD25+Foxp3+ CCR2-transfected T cell; MRL/
lpr, MRL/MpJ-lpr/lpr; Treg cell, CD4+CD25+Foxp3+ T cell.Available online http://arthritis-research.com/content/9/1/R15
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Naturally occurring CD4+CD25+  regulatory T cells, which
show high expression of Foxp3, are essential for the mainte-
nance of peripheral tolerance through their suppression of
autoreactive T cells [1,2]. CD4+CD25+ regulatory T cells are
able not only to suppress CD4+ and CD8+ T-cell responses
but also to affect the functions of a variety of cells, including B,
NK, NKT, and dendritic cells [6-10]. Naturally occurring
CD4+CD25+  regulatory T cells are not suppressive and
require T-cell receptor interaction with a specific antigen or
polyclonal stimulus to exert suppression. However, once acti-
vated, they are able to suppress the proliferation and activation
of CD4+ and CD8+ T cells. Because the CD4+CD25+ T cell
population is heterogeneous, containing activated nonregula-
tory CD25+  T cells, there have been some contradictory
reports about the mechanisms of suppression. However, the
suppressive function of CD4+CD25+ regulatory T cells is gen-
erally considered to be cell contact-dependent and cytokine-
independent, although the molecular nature of the contact-
Figure 6
Kinetics of Foxp3 expression in the tissues after transfer of Treg and CCR2-Treg cells Kinetics of Foxp3 expression in the tissues after transfer of Treg and CCR2-Treg cells. (a) Five hundred thousand Treg or CCR2-Treg cells were 
injected into the retro-orbital vein of 14-week-old MRL/lpr mice. Then, the lungs and submandibular glands were harvested at 3 hours, 24 hours, 72 
hours, 5 days, and 7 days after transfer. Quantitative real-time polymerase chain reaction analysis was performed on total RNA prepared from the 
above tissues. Results are calculated as a ratio of Foxp3 expression to the expression of hypoxanthine phosphoribosyl transferase 1 (HPRT1). (b) 
Analysis of the mononuclear cells in the lungs and submandibular glands of MRL/lpr mice after transfer of Treg and CCR2-Treg cells. The mononu-
clear cells in the lungs and submandibular glands were harvested at 3 hours and 24 hours after transfer as described in Materials and methods and 
analyzed by immunofluorescence on an Olympus IX70 inverted microscope. CCR2-Treg cells contain green fluorescent protein and red fluorescent 
protein (DsRed), whereas Treg cells contain only DsRed. Results are shown as a percentage of staining cells (Treg or CCR2-Treg cells) (n = 3 or 4 
mice per group). CCR2-Treg cell, CD4+CD25+Foxp3+ CCR2-transfected T cell; Foxp3, forkhead box p3; MRL/lpr, MRL/MpJ-lpr/lpr; Treg cell, 
CD4+CD25+Foxp3+ T cell.Arthritis Research & Therapy    Vol 9 No 1    Hasegawa et al.
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dependent interaction has not been fully established.
Therefore, for CD4+CD25+ regulatory T cells to function effi-
ciently, it is necessary to accumulate them in target organs.
There is also contradictory information about the chemotactic
activity of CD4+CD25+ regulatory T cells. CD4+CD25+ regu-
latory T cells have been reported to express CCR4, CCR5,
CCR7, and CCR8 and to be chemoattracted by their respec-
tive ligands, CCL22, CCL4, CCL19, and CCL1 [32-35]. How-
ever, Gavin and colleagues [36] showed that CD4+CD25+
regulatory T cells were refractory to lymphoid chemokines
such as MCP-1, CCL4, CCL19, CCL21, CCL22, and
CXCL12. In addition, there are contradictory data about
CCR2 expression on CD4+CD25+CD62+ T cells [35,37].
These discrepancies among the various reports may be
because of small variations in the experimental protocol or
mouse strains used, but a more important reason may be that
distinct cell subsets have unique chemokine responses, and
most of the previous studies did not examine these subsets. In
the present study, cultured Treg cells had no, or only very low,
MCP-1-directed chemotactic activity, whereas CCR2-Treg
cells exhibited marked MCP-1-directed chemotaxis.
Pneumonitis and sialadenitis in MRL/lpr mice become notice-
a b l e  a t  1 0  t o  1 2  w e e k s  o f  age and progress with age
thereafter. Although the mechanism of pneumonitis in MRL/lpr
mice is still unknown, disease severity is associated with the
degree of mononuclear cell infiltration in the perivascular, per-
ibronchial, and alveolar areas [38]. From our results and other
reports, it appears that MCP-1 and IP-10 play an important
role in the infiltration of these cells into the lung of MRL/lpr
mice [24,26,27]. The development of pneumonitis in MRL/lpr
mice is characterized by the accumulation of T cells, especially
CD4-CD8-B220+ and CD4+ T cells [26]. Although the lym-
phadenopathy in MRL/lpr mice is due to accumulation of CD4-
CD8-B220+ T cells, features of autoimmunity such as produc-
tion of autoantibodies, arthritis, and sialadenitis depend mainly
on CD4+ T cells [39]. Furthermore, activated and clonally
expanded CD4+ T cells, which might recognize restricted T-
cell epitopes on autoantigens, have been reported to accumu-
late in the lung of MRL/lpr mice [40]. These findings suggest
that CD4+ T cells rather than CD4-CD8-B220+ T cells play a
critical role in the pathogenesis of pneumonitis in MRL/lpr
mice. Sialadenitis in MRL/lpr mice is also characterized his-
topathologically by initial mononuclear cell infiltration into peri-
ductular regions, followed by progressive destruction of
ductules and parenchyma, resembling the features of Sjögren
syndrome. The inflammatory infiltrate consists predominantly
of CD4+ T cells. Our studies have shown that MCP-1 and IP-
10 are expressed predominantly in infiltrating macrophages/
monocytes and ductal epithelium, respectively, beginning at
the early stage of sialadenitis in MRL/lpr mice [22]. Therefore,
these chemokines seem to be involved in the process of
mononuclear cell infiltration.
On the basis of these results, we investigated whether pneu-
monitis and sialadenitis in MRL/lpr mice could be ameliorated
by accumulation of CCR2-expressing CD4+CD25+ regulatory
T cells in target organs. Adoptive transfer of 5 × 105 Treg cells
showed little effect on the production of autoantibodies and
disease progression. In contrast, transfer of CCR2-Treg cells,
even in smaller numbers, ameliorated the progression of both
pneumonitis and sialadenitis. This was because sufficient
numbers of regulatory T cells to suppress the proliferation and
activation of autoreactive T cells, especially CD4+ T cells,
migrated into the target organs. On the other hand, there was
no significant difference in renal damage among control MRL/
lpr mice and mice that underwent transfer of Treg cells or
CCR2-Treg cells. Two reasons for this can be considered.
One is that the number of cells that migrated into the kidney
was insufficient to reduce renal damage. The other is that Treg
cells may have had little effect on reduction of renal damage
given that macrophages rather than T cells play an important
role in the development of nephritis in MRL/lpr mice.
Adoptive transfer of naturally occurring or cultured polyclonal
CD4+CD25+  regulatory T cells has been shown to exert
potentially therapeutic effects on autoimmune diseases in
many animal models [1,2]. However, the numbers of trans-
ferred CD4+CD25+ regulatory T cells are small and work bet-
ter in a local and specific manner since these cells suppress
the immune response to tumors and infections. The use of anti-
gen-specific regulatory T cells has been shown to have the
most potential for therapy of organ-specific autoimmune dis-
eases in animal models [11-16]. However, in the majority of
autoimmune diseases in humans, the organ-specific antigens
remain undefined. Therefore, although some problems such as
the most effective vector to employ for humans remain unre-
solved, in the future our method may have useful applications
not only for treatment of autoimmune diseases but also for
management of transplant rejection and GVHD in humans.
Conclusion
In the present study, we prepared CCR2-expressing Treg
cells and demonstrated their ability to ameliorate pneumonitis
and sialadenitis in MRL/lpr mice by accumulating in target
organs. In the future, this method may provide a new
therapeutic approach for organ-specific autoimmune diseases
in which the target antigens remain undefined.
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